Signal Transduction Inhibitors in Renal Cell Carcinoma
| Autor: | Ellen A. Ronnen, Robert J. Motzer, Saby George, Ronald M. Bukowski |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Sorafenib
Tumor suppressor gene business.industry Sunitinib medicine.drug_class medicine.medical_treatment urologic and male genital diseases medicine.disease female genital diseases and pregnancy complications Tyrosine-kinase inhibitor Targeted therapy Vascular endothelial growth factor chemistry.chemical_compound chemistry Renal cell carcinoma medicine Cancer research business neoplasms Tyrosine kinase medicine.drug |
| Zdroj: | Clinical Management of Renal Tumors ISBN: 9781588292513 |
| DOI: | 10.1007/978-1-60327-149-3_25 |
| Popis: | Metastatic renal cell carcinoma (RCC) has been characterized by a resistance to systemic chemotherapy and poor overall survival. Cytokine therapy, the mainstay of treatment, provides responses in a minority of patients. The discovery of the VHL tumor suppressor gene, hypoxia inducible factor-1α (HIF-1α), and their roles in the growth of RCC identified a pathway on which to direct targeted therapy. Vascular endothelial growth factor (VEGF) plays a central role in RCC and has been a focus of multiple agents in clinical trials. Small molecule tyrosine kinase inhibitors, monoclonal antibodies, and novel agents are all being studied. Phase II studies show promising activity of sunitinib, sorafenib, and bevacizumab, and early results of phase III studies demonstrate the role of these agents in metastatic RCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|